ORIC Pharmaceuticals, Inc. (ORIC)
| Market Cap | 969.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -129.47M |
| Shares Out | 100.36M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,620,852 |
| Open | 10.35 |
| Previous Close | 10.19 |
| Day's Range | 9.47 - 10.35 |
| 52-Week Range | 4.52 - 14.93 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 19.73 (+104.24%) |
| Earnings Date | May 5, 2026 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price target is $19.73, which is an increase of 104.24% from the latest price.
News
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ORIC--ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). The investigation focuses on O...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...
ORIC Pharmaceuticals Transcript: Study update
Rinzimetostat at 400 mg daily with darolutamide showed strong efficacy and a highly differentiated safety profile in mCRPC, supporting its selection as the phase III dose. Landmark RPFS and ctDNA responses were robust, and safety was superior to competitor regimens, positioning it for significant commercial potential.
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Two clinical-stage oncology programs are advancing, with rinzimetostat set for a phase III prostate cancer trial and enosertinib showing strong CNS activity in lung cancer. Key data updates and competitor readouts this year will shape future strategies and potential market expansion.
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization i...
ORIC Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Development is advancing for two lead oncology programs, with phase III trials and key data updates planned for 2024. Early clinical results show promising efficacy and safety, and the company is well-funded through 2028 to support these milestones.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
ORIC Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Two late-stage oncology assets are advancing to phase III, with rinzimetostat showing strong efficacy and safety in prostate cancer and enozertinib demonstrating 100% intracranial response in lung cancer. Key data readouts and trial initiations are expected in 2025-2027.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combin...
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
ORIC Pharmaceuticals Transcript: Status Update
ORIC-114 shows strong systemic and CNS efficacy in EGFR-mutated NSCLC, with high response rates and a favorable safety profile at 80 mg. The drug’s robust brain penetrance and lack of significant off-target toxicities position it as a potential best-in-class therapy, with Phase 3 trials planned and a significant commercial opportunity projected.
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development pl...
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET
ORIC Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant clinical progress was made in 2025, with ORIC-944 showing promising efficacy and safety in prostate cancer and ORIC-114 poised for key data at ESMO Asia. The company is well-funded, planning a phase III start for ORIC-944 in early 2026, and sees substantial market opportunities in both programs.
Top 3 Health Care Stocks That May Rocket Higher In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
ORIC Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Lead oncology programs are advancing toward phase III, with ORIC-944 showing strong efficacy, safety, and ctDNA clearance in prostate cancer. ORIC-114 is progressing in lung cancer, with pivotal studies planned for both assets and a cash runway into 2028.